Iron in nonhemochromatotic liver disorders

Seminars in Liver Disease

Volumn 25, Issue 4, 2005, Pages 461-472

  Alla, Vamsee ^a   Bonkovsky, Herbert L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Alcohol; Cirrhosis; Hepatitis C; Iron; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Porphyria cutanea tarda

Indexed keywords

HEPCIDIN; IRON; LIPID; NUCLEIC ACID; PROTEIN; REACTIVE OXYGEN METABOLITE;

ALCOHOL LIVER DISEASE; BIOACCUMULATION; BIOSYNTHESIS; CHRONIC HEPATITIS; COMORBIDITY; CYSTIC FIBROSIS; CYTOPATHOGENIC EFFECT; DISEASE ASSOCIATION; GENE MUTATION; HEART MUSCLE FIBROSIS; HEMOCHROMATOSIS; HEPATITIS C; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; IRON STORAGE; LIPID OXIDATION; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHEMOCHROMATOTIC LIVER DISEASE; NONHUMAN; OXIDATIVE STRESS; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

FATTY LIVER; HEPATITIS C; HUMANS; IRON; LIVER CIRRHOSIS; OXIDATIVE STRESS; PORPHYRIA CUTANEA TARDA; RISK FACTORS;

EID: 28444435827     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-923317     Document Type: Review

References (120)

1. Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology 2004;126:1293-1301
2. Bonkovsky HL, Obando JV. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis. Curr Gastroenterol Rep 1999;1:30-37
3. Milman N, Graudal N, Hegnhoj J, Christoffersen P, Pedersen NS. Relationships among serum iron status markers, chemical and histochemical liver iron content in 117 patients with alcoholic and non-alcoholic hepatic disease. Hepatogastroenterology 1994;41:20-24
4. De Feo TM, Fargion S, Duca L, et al. Non-transferrinbound iron in alcohol abusers. Alcohol Clin Exp Res 2001;25:1494-1499
5. Suzuki Y, Saito H, Suzuki M, et al. Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease. Alcohol Clin Exp Res 2002;26(8 Suppl):26S-31S
6. Pascoe A, Kerlin P, Steadman C, et al. Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation. Gut 1999;45:301-305
7. Pascoe A, Kerlin P, Jones D. Spur cell anemia explains the iron overload in advanced cirrhosis (C282Y negative). Hepatology 2000;32:159
8. Mazzanti R, Srai KS, Debnam ES, Boss AM, Gentili P. The effect of chronic ethanol consumption on iron absorption in rats. Alcohol Alcohol 1987;22:47-52
9. Duane P, Raja KB, Simpson RJ, Peters TJ. Intestinal iron absorption in chronic alcoholics. Alcohol Alcohol 1992;27:539-544
10. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003;30:137-144
11. Harrison-Findik D, Schafer D, Klein E, Gollan J. Hepatic hepcidin expression is regulated by ethanol and acetaldehyde: role of IL-6 and oxidative stress. BioIron 2005: Prague, Czech Republic; 2005:24
12. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093
13. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004;350:2383-2397
14. Sabesin SM, Thomas LB. Parenchymal siderosis in patients with preexisting portal cirrhosis. A pathologic entity simulating idiopathic and transfusional hemochromatosis. Gastroenterology 1964;46:477-485
15. Powell LW. Normal human iron storage and its relation to ethanol consumption. Australas Ann Med 1966;15:110-115
16. Lundvall O, Weinfeld A, Lundin P. Iron stores in alcohol abusers. I. Liver iron. Acta Med Scand 1969;185:259-269
17. Jakobovits AW, Morgan MY, Sherlock S. Hepatic siderosis in alcoholics. Dig Dis Sci 1979;24:305-310
18. MacDonald RA. Primary hemochromatosis: inherited or acquired? Prog Hematol 1966;5:324-353
19. Regoeczi E, Chindemi PA, Debanne MT. Transferrin glycans: a possible link between alcoholism and hepatic siderosis. Alcohol Clin Exp Res 1984;8:287-292
20. Beguin Y, Bergamaschi G, Huebers HA, Finch CA. The behavior of asialotransferrin-iron in the rat. Am J Hematol 1988;29:204-210
21. Rouach H, Houze P, Gentil M, Orfanelli MT, Nordmann R. Effects of acute ethanol administration on the uptake of 59Fe-labeled transferrin by rat liver and cerebellum. Biochem Pharmacol 1994;47:1835-1841
22. Chapman RW, Morgan MY, Boss AM, Sherlock S. Acute and chronic effects of alcohol on iron absorption. Dig Dis Sci 1983;28:321-327
23. Tsukamoto H, Horne W, Kamimura S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 1995;96:620-630
24. Adams PC, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 1996;23:724-727
25. Loreal O, Deugnier Y, Moirand R, et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol 1992;16(1-2):122-127
26. Fargion S, Mandelli C, Piperno A, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15:655-659
27. Fargion S, Fracanzani AT, Piperno A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994;20:1426-1431
28. Fletcher LM, Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol 2003;30:131-136
29. Grove J, Daly AK, Burt AD, et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 1998;43:262-266
30. Thursz M, Mantafounis D, Yallo R. Severe alcoholic liver disease is associated with the haemochromatosis gene mutant. Gastroenterology 1997;112:A1401
31. Frenzer A, Rudzki Z, Norton ID, Butler WJ, Roberts-Thomson IC. Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis. Scand J Gastroenterol 1998;33:1324
32. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-638
33. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis 1996;16:65-82
34. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-1669
35. Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin Liver Dis 2000;4:409-429, vi-viii
36. Lambrecht RW, Bonkovsky HL. Hemochromatosis and porphyria. Semin Gastrointest Dis 2002;13:109-119
37. Elder GH, Sheppard DM, De Salamanca RE, Olmos A. Identification of two types of porphyria cutanea tarda by measurement of erythrocyte uroporphyrinogen decarboxylase. Clin Sci (Lond) 1980;58:477-484
38. Koszo F, Morvay M, Dobozy A, Simon N. Erythrocyte uroporphyrinogen decarboxylase activity in 80 unrelated patients with porphyria cutanea tarda. Br J Dermatol 1992;126:446-449
39. Elder GH, Urquhart AJ, De Salamanca RE, Munoz JJ, Bonkovsky HL. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet 1985;2:229-233
40. Gorman N, Ross KL, Walton HS, et al. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron. Hepatology 2002;35:912-921
41. Sinclair PR, Gorman N, Walton HS, et al. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 2000;162:60-67
42. Sinclair PR, Gorman N, Dalton T, et al. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2( - / - ) null mutant mice. Biochem J 1998;330(Pt 1):149-153
43. Smith AG, Clothier B, Carthew P, et al. Protection of the Cyp1a2( - / - ) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzop-dioxin. Toxicol Appl Pharmacol 2001;173:89-98
44. Sinclair PR, Gorman N, Trask HW, et al. Uroporphyria caused by ethanol in Hfe( - / - ) mice as a model for porphyria cutanea tarda. Hepatology 2003;37:351-358
45. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321-323
46. Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000;95:1565-1571
47. Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002;47:419-426
48. Tannapfel A, Stolzel U, Kostler E, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 2001;439:1-5
49. Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998;28:404-409
50. Sampietro M, Piperno A, Lupica L, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998;27:181-184
51. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967
52. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657
53. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438
54. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845
55. Loguercio C, De ST, D'Auria MV, et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 2004;36:398-405
56. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455
57. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850
58. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver-an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73-79
59. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999;18:353-358
60. Tankurt E, Biberoglu S, Ellidokuz E, et al. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis. J Hepatol 1999;31:963
61. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192
62. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-2961
63. Loguercio C, De Girolamo V, de Sio I, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 2001;35:568-574
64. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379
65. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-372
66. Comert B, Mas MR, Erdem H, et al. Insulin resistance in non-alcoholic steatohepatitis. Dig Liver Dis 2001;33:353-358
67. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109
68. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318
69. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421-429
70. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362
71. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30:847-850
72. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122:931-939
73. Desai T, Chiorean M. Phlebotomy reduces transaminase levels in patients with chronic non-alcoholic steatohepatitis. Gastroenterology 1998;114:A1233
74. Nitecki J, Jackson F, Allen M. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH). Gastroenterology 2000;118:A1474
75. Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003;124:866-867
76. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem 2005;51:1201-1205
77. [No authors listed.]. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47
78. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999;31(Suppl 1):88-91
79. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466
80. Seeff LB. The natural history of chronic hepatitis C virus infection. Clin Liver Dis 1997;1:587-602
81. Blumberg BS, Lustbader ED, Whitford PL. Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci USA 1981;78:3222-3224
82. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113
83. Arber N, Konikoff FM, Moshkowitz M, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994;39:2656-2659
84. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-768
85. Shan Y, Lambrecht RW, Bonkovsky HL. Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. Clin Infect Dis 2005;40:834-841
86. Sartori M, Andorno S, La TG, et al. Evaluation of iron status in patients with chronic hepatitis C. Ital J Gastroenterol Hepatol 1998;30:396-401
87. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995;103:419-424
88. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to Interferon in chronic hepatitis C. Am J Gastroenterol 1996;91:1367-1373
89. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to Interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-415
90. Olynyk JK, Reddy KR, Di Bisceglie AM, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995;108:1104-1109
91. Piperno A, Sampietro M, D'Alba R, et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-254
92. Fargion S, Fracanzani AL, Sampietro M, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997;9:497-503
93. Fong TL, Han SH, Tsai NC, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998;28:369-374
94. Fontana RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-736
95. Fargion S, Fracanzani AL, Rossini A, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002;97:1204-1210
96. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-138
97. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997;92:1831-1834
98. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988
99. Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R. Chronic hepatitis C is mild in menstruating women. J Gastroenterol Hepatol 2000;15:1411-1417
100. Yano M, Hayashi H, Wakusawa S, et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002;97:133-137
101. Kimura F, Hayashi H, Yano M, et al. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C. Hepatogastroenterology 2005;52:563-566
102. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
103. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
104. Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol 2002;97:1-4
105. Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997;41:115-120
106. Piperno A, Vergani A, Malosio I, et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998;28:1105-1109
107. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699
108. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127-134
109. Martinelli AL, Franco RF, Villanova MG, et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol 2000;102:152-156
110. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003;124:318-326
111. Bonkovsky HL, Troy N, McNeal K, et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002;37:848-854
112. de Sousa M, Porto G. The immunological system in hemochromatosis. J Hepatol 1998;28(Suppl 1):1-7
113. Pietrangelo A, Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003;124:1509-1523
114. Lustbader ED, Hann HW, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983;220:423-425
115. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810
116. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA 2005;102:1324-1328
117. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-22
118. Detivaud L, Nemeth E, Boudjema K, et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746-748
119. Ohtake T, Inoue M, Miyoshi S, Suzuki Y, Saito H, Kohgo Y. Hepcidin is decreased in alcohol abuse. BioIron 2005: Prague, Czech Republic 2005:73
120. Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol 2005;39:71-74